Ajulemic acid

点击蓝字 · 关注我们 皮肌炎是一种罕见却棘手的自身免疫性疾病，它像一个“双面杀手”，同时侵袭皮肤和肌肉，导致红疹、肌肉无力，甚至危及肺部和心脏。全球发病率约5-10/100万，在中国，这一数字更高。但别担心！随着医学的迅猛发展，DM从“不治之症”转为“可控慢性病”。 2025年最新指南显示，早期联合治疗可让70%以上患者实现缓解。 本文将带你全面探索现有药物选择及国内外在研前沿，逐一剖析每种药物的原理，帮助你从科学角度把握治疗逻辑。无论你是患者还是家属，这份攻略将点燃你的希望之火！ 01 从基础到精准，层层把控疾病 DM治疗遵循“早期、联合、个体化”原则，通常以糖皮质激素为基础，辅以免疫抑制剂、生物制剂和IVIG。中国专家共识强调中西结合，融入中药辅助。 现有药物主要分为几类，每类我们都简述原理、适用和注意事项。 1. 糖皮质激素：快速“灭火”，一线首选 这些药物是DM治疗的“急救队”，能迅速抑制炎症，但长期使用需警惕副作用。 泼尼松或泼尼松龙（Prednisone/Prednisolone）：原理：通过抑制细胞因子产生和免疫细胞活性，减少炎症和自身免疫反应。适用于初始诱导缓解，剂量1-2 mg/kg/日口服。在中国，常用于成人DM首诊。 效果：短期内改善肌肉力量和皮肤症状，但易致骨质疏松、糖尿病。严重时用静脉甲基泼尼松龙脉冲（0.5 g/日，3天）。 2. 免疫抑制剂：减少激素依赖，长期维护 这些是“二线守护者”，通过调控免疫系统，控制疾病进程。常与激素联合。 硫唑嘌呤（Azathioprine）：原理：抑制DNA/RNA合成，减少T细胞增殖和免疫响应。适用于中重度DM，剂量1-3 mg/kg/日。效果：6-8周见效，安全用于妊娠期，但需监测骨髓抑制和肝毒性。 甲氨蝶呤（Methotrexate）：原理：提升腺苷水平，抑制免疫激活和炎症。剂量7.5-25 mg/周口服或皮下。适用于激素响应不足者，但ILD患者慎用，以防肺纤维化。 霉酚酸酯（Mycophenolate Mofetil, MMF）：原理：抑制T/B淋巴细胞增殖、抗体产生和白细胞趋化。剂量2-3 g/日，首选于DM伴ILD，能改善肺功能。4-8周生效，副作用包括感染和胃肠不适。 环孢素A（Cyclosporin A）和他克莫司（Tacrolimus）：原理：阻断钙调磷酸酶，抑制T细胞激活。剂量分别为2.5-5 mg/kg/日和0.1-0.2 mg/kg/日。适用于难治性DM或ILD，但易致肾毒性和高血压。 环磷酰胺（Cyclophosphamide）：原理：DNA烷基化，抑制免疫细胞增殖。静脉脉冲0.5-2 g/m²/月，用于严重ILD，尤其是抗MDA5阳性DM。效果显著，但风险包括骨髓抑制和膀胱炎。 在中国，中药如雷公藤多苷常辅助，原理：免疫抑制，减少炎症，常与西药联合降低副作用。 除此之外，现在皮肌炎/多发性肌炎可报名CAR-T细胞治疗，Anifrolumab等，入组成功后，可安排就近的三甲医院免费用药，点击下方申请用药报名 ↓ ↓ ↓ 3. IVIG和生物制剂：针对难治，精准打击 当以上无效时，转向这些“高端武器”。 静脉注射免疫球蛋白（IVIG）：原理：中和自身抗体，调控细胞因子平衡和补体沉积。剂量2 g/kg/4周，用于严重或难治DM，包括肺和食管受累。随机试验证实改善肌肉力量，耐受性好，但注意过敏和血栓。 Octagam 10%已在国内外广泛应用。 利妥昔单抗（Rituximab）：原理：靶向CD20耗竭B细胞，减少自身抗体产生。剂量375 mg/m²/周或1 g两次。适用于难治DM伴ILD，缓解率达83%。副作用：输注反应和感染。 托珠单抗（Tocilizumab）：原理：阻断IL-6受体，抑制炎症信号。用于难治性快速进展ILD，但24周试验未达主要终点，仍有救助潜力。 阿巴西普（Abatacept）：原理：阻断T细胞共刺激，调控免疫激活。IIb期试验显示有效于难治DM。 TNF-α抑制剂（如依那西普、英夫利昔单抗、阿达木单抗）：原理：阻断TNF-α信号，减少炎症。依那西普（50 mg/周皮下）用于难治DM；英夫利昔单抗针对并发症；阿达木单抗治疗钙质沉着。疗效不一，需进一步验证。 JAK抑制剂（如托法替尼、乌帕替尼）：原理：竞争抑制JAK酶，阻断促炎细胞因子信号（如干扰素通路）。托法替尼（5-10 mg/日）用于难治DM伴ILD，改善存活和肺功能；乌帕替尼（15 mg/日）选择性强，但注意感染和血栓风险。这些已在2025年成为新兴标准。 02 新兴药物涌现，精准疗法指日可待 尽管现有药物已让DM管理更有效，但仍有20%-30%患者难治。2025年，国内外管道药物聚焦新型靶点，如干扰素、JAK和免疫调节，预计2034年市场将翻番。 以下亮点，每种简述原理。1. 新兴小分子和生物制剂 Brepocitinib (Priovant/Pfizer)：原理：TYK2/JAK1双抑制剂，阻断炎症信号通路。III期试验中，用于DM，预期改善肌肉和皮肤症状。中国参与全球试验。 M5049 High Dose：原理：TLR7/8抑制剂，调控先天免疫，减少炎症。管道中，针对DM。 Lenabasum 20 mg：原理：大麻素受体CB2激动剂，抗炎和纤维化。II/III期，用于DM皮肤症状。 GLPG3667：原理：选择性TYK2抑制剂，抑制干扰素信号。管道中。 PN-101：原理：新型免疫调节剂，针对DM特定抗体。韩国/中国开发。 KZR-616：原理：免疫蛋白酶体抑制剂，调控淋巴细胞功能。II期，用于肌炎。2. 先进生物疗法 Efgartigimod (argenx)：原理：FcRn拮抗剂，加速IgG降解，减少自身抗体。EULAR 2025数据显示，对肌炎有效，中国有临床跟进。 Dazukibart (PF-06823859)：原理：干扰素β抑制剂，针对DM炎症核心。管道中。 Anifrolumab (SAPHNELO)：原理：I型IFN受体拮抗剂，阻断干扰素信号。用于DM，2025年试验活跃。 HIZENTRA：原理：皮下免疫球蛋白，类似IVIG但更方便。用于维持。 中国方面，南京百恒生物（Nanjing Bioheng Biotech）正开发细胞疗法，如CAR-T针对DM。 此外，研究强调抗MDA5+ DM的个性化治疗。 除此之外，现在皮肌炎/多发性肌炎可报名CAR-T细胞治疗，Anifrolumab等，入组成功后，可安排就近的三甲医院免费用药，点击下方申请用药报名 ↓ ↓ ↓ 小结：行动起来，拥抱新生 从激素到JAK抑制剂，DM治疗已进入精准时代；在研药物如Brepocitinib预示着“零副作用”未来的可能。中国共识呼吁中西结合，患者应及早咨询风湿免疫科，监测抗体和肺功能。如果你正与DM抗争，别犹豫——希望就在前方！CAR-T细胞疗法正在招募中，扫码即可报名。 😊 皮肌炎/多发性肌炎免费用药/临床招募 全国70+城市三甲医院正开展临床试验，符合条件者可享： 免费用药：治疗期间药物及检查全免 交通补助：每次随访高额补贴 专业随访：由专家团队全程监测 就近三甲医院用药！立即扫码报名，抢占免费用药名额！ END 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删  往期推荐 CAR-T细胞疗法：重塑皮肌炎治疗的新希望（CAR-T细胞疗法招募中） argenx在EULAR 2025上惊艳亮相：Efgartigimod为皮肌炎患者带来新曙光 （CAR-T治疗法皮肌炎招募）皮肌炎治疗重大突破！CAR-T疗法实现停药缓解，临床研究显示缓解率超80%。 点点赞 点分享 点喜欢 关注风湿免疫药研之声 了解更多新药资讯

Throughout history, cannabis has been utilized as a medicinal substance, derived from plants of the Cannabis genus. Its principal constituents are Tetrahydrocannabinol (THC) and Cannabidiol (CBD). Cannabinoids are a group of terpenophenolic compounds discovered within cannabis and also occur naturally in the nervous and immune systems of animals. In the 1980s, researchers identified two G protein-coupled receptors that exhibit specific responses to cannabinoids: the cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2). Cannabinoid receptors and endogenous cannabinoids are not only involved in regulating numerous physiological functions of the central and peripheral nervous systems but also play a role in regulating the physiological functions of many peripheral sites in the human body, including the endocrine system, immune system, gastrointestinal tract, cardiovascular system, and reproductive system. CB1 receptors, although primarily found in the brain, are also expressed in the spleen, lungs, thymus, heart, and blood vessels. Within the central nervous system, their expression is highest at the axons and presynaptic terminals of neurons in the amygdala, hippocampus, cortex, basal ganglia, and cerebellum. They are closely associated with GABAergic (inhibitory) and glutamatergic (excitatory) neurons, mediating the sustained release of inhibitory and excitatory neurotransmitters. CB2 receptors are most abundantly found in tissues with immune functions outside the brain (such as the spleen, tonsils, bone marrow, pancreas, peripheral blood leukocytes) and within the brain (astroglia and microglia). They play a role in regulating immune cell migration and cytokine release, and are also involved in the cardiovascular and respiratory systems, bones, gastrointestinal tract, liver, and reproductive system. Cannabinoids can be categorized into three types based on their origin: endocannabinoids, phytocannabinoids, and synthetic cannabinoids. Endocannabinoids are chemicals produced within the human body that attach to the same receptors (CB1 and CB2) as certain plant-derived cannabinoids. These endogenous chemical substances help in maintaining equilibrium and harmony in a healthy body. The two most extensively studied endocannabinoids, anandamide and 2-AG, along with the enzymes responsible for their metabolism, constitute the endocannabinoid system. The molecular targets of anandamide and 2-AG, along with other phytocannabinoids, are not just CB1 and CB2, but also include TRPR and GPR55. A key characteristic of endocannabinoids is that their precursors are present in lipid membranes, from which they can be synthesized through one or two rapid enzymatic steps and released into the extracellular space. Phytocannabinoids are chemical substances found and extracted from the cannabis plant. The cannabis plant contains over 100 known phytocannabinoids, with the highest concentration typically found in the unfertilized flower buds of female plants. THC (Tetrahydrocannabinol) and CBD (Cannabidiol) are the most extensively studied phytocannabinoids. Currently, only one phytocannabinoid product has been approved by the U.S. FDA, which is a CBD oral solution approved for the treatment of seizures associated with rare forms of epilepsy. The term "medical marijuana," which is not FDA-approved, lacks a scientific definition but is generally understood to be a product containing phytocannabinoids from the cannabis plant, intended to alleviate the symptoms of diseases. Synthetic cannabinoids are chemical substances created in a laboratory to mimic plant cannabinoids. The United States FDA has approved three synthetic cannabinoid products that imitate the plant cannabinoid THC. Synthetic cannabinoids may be more potent than tetrahydrocannabinol (THC) extracted from cannabis. The FDA-approved synthetic THC formulations Nabilone (sold under the brand name Cesamet) and Dronabinol (sold under the brand names Marinol and Syndros) are used for the treatment of nausea and vomiting associated with cancer chemotherapy; Dronabinol is also indicated for the treatment of anorexia associated with weight loss in patients with AIDS. According to statistics from the Synapse database, there are a total of 256 drug development pipelines worldwide targeting the cannabinoid receptors (CB1 and CB2). Approximately 119 projects (46%) are at the non-research phase, while 74 pipelines (29%) are at the pre-clinical research stage. Five drugs have been approved for the market, including Cannabidiol, Dronabinol, and Rimonabant. Six drug candidates are in the clinical phase 2/3 or phase 3 study stages, and 23 are in clinical phase 2. Apart from the development of subtype-selective therapeutic drugs for CB1 or CB2, some pharmaceutical research efforts focus on developing non-selective CB1/CB2 drug molecules and multi-target drugs that act on both CB1/2 and other receptors such as 5-HT1A and NMDA receptors. Clinical indications and drug development opportunities targeting CB1 and CB2 receptors include: treatments for neurological disorders (such as neuropathic pain, epilepsy, Parkinson's disease, etc.), metabolic diseases (such as obesity, type 2 diabetes, non-alcoholic fatty liver disease, etc.), pain management (pain and neuropathy), immune system modulation (such as rheumatoid arthritis, inflammatory bowel disease, etc.), anti-cancer therapies, and interventions for substance addiction and mental health, among others. Novel therapeutics targeting CB1 and CB2 receptors may comprise agonists, antagonists, partial agonists, biased agonists, allosteric modulators, etc., to more precisely regulate the activity of the endocannabinoid system and reduce side effects. Cannabidiol/Dronabinol (CBD/THC) is a medication developed by GW Pharmaceuticals for the treatment of sleep initiation and sleep disorders, which was first approved for sale in Germany in 2022. Cannabidiol is an active cannabinoid found in cannabis, which can be extracted from cannabis or hemp plants. It is used to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, as well as relief for moderate to severe neuropathic pain or other pain symptoms. While its precise medical impact is under investigation, Cannabidiol has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic, and it has also shown neuroprotective, anti-inflammatory, and antioxidant activities. Dronabinol is a synthetic Δ9-tetrahydrocannabinol (Δ⁹-THC) that functions through mild partial agonist activity on CB1 and CB2 receptors, producing effects known from cannabis consumption such as increased appetite, pain relief, and altered mood and cognitive processes. It has been approved in various countries and regions for treating anorexia associated with weight loss in AIDS patients, as well as for nausea and vomiting caused by chemotherapy in cancer patients who have not responded adequately to conventional antiemetic treatments. GW Pharmaceuticals has established a world-leading cannabinoid science platform for the development of a deep, innovative portfolio of early and late-stage cannabinoid product candidates, along with highly specialized cultivation and manufacturing technologies. GW was also the first to develop and commercialize the world's first prescription medicine derived from the cannabis plant. Unlike CBD products or cannabis derivatives not approved by the FDA, GW's portfolio of regulator-approved products ensures that each of them undergoes a thorough evaluation of safety and efficacy through clinical trials, independent peer reviews, regulator approvals, and is consistently produced to the highest quality standards. In 2021, JAZZ Pharmaceuticals acquired GW Pharmaceuticals for $7.2 billion. Rimonabant is an anorectic anti-obesity drug originally researched, developed, produced, and marketed by the company Sanofi-Aventis. It acts as a reverse agonist for the cannabinoid receptor CB1, with its primary mechanism of action being the reduction of appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use globally, and after its initial market approval in 2006, it received authorization in 38 countries including the European Union, Mexico, and Brazil. However, its application for market approval was rejected by the U.S. FDA due to potential risks of increased suicidal thoughts and depression. Early clinical observations noted that cannabis stimulates appetite, suggesting the involvement of the endogenous cannabinoid system in the control of energy balance. Rimonabant was the first CB1 receptor antagonist to be marketed and was developed as an anti-obesity drug intended to decrease food intake by blocking central cannabinoid activity. Around 2005-2006, Sanofi-Aventis and clinical research teams published articles in "The Lancet" (two papers) and "The New England Journal of Medicine," discussing the effects of Rimonabant on weight reduction and cardiovascular risk factors in overweight patients, the influence on metabolic risk factors in patients with overweight dyslipidemia, and the efficacy and tolerability in overweight or obese patients with type 2 diabetes. The results indicate that for overweight or obese patients with Type 2 diabetes who exhibit inadequate glycemic control with metformin or sulfonylureas, a combined treatment of 20 mg/day Rimonabant with diet and exercise can lead to weight reduction and improvement in HbA1c, as well as a range of cardiovascular and metabolic risk factors, which is clinically significant. However, a meta-analysis of all published randomized controlled trials has shown that taking 20 mg of Rimonabant daily increases the risk of psychiatric adverse events (mood disorders including depressive disorders and anxiety). Adverse events associated with Rimonabant were significantly more frequent than with placebo, with severe adverse events occurring 1.4 times more often than with placebo. Patients taking Rimonabant were 2.5 times more likely to discontinue treatment due to depressive mood disorders compared to those receiving a placebo. The U.S. FDA analyzed four major trials as well as unpublished studies and found that taking Rimonabant (20 mg/day) resulted in a higher incidence of psychiatric adverse reactions compared to placebo. Furthermore, it was reported that two patients taking Rimonabant died from suicide. The United States never approved the drug for the treatment of obesity. Subsequently, European regulatory authorities revoked the marketing authorization for Rimonabant. Taranabant is a small molecule CB receptor inverse agonist originally developed by Merck & Co. It is reported that phase 3 clinical trial data for taranabant in overweight patients showed a weight reduction effect similar to that of Rimonabant. However, due to potential side effects and other reasons, Merck & Co. terminated the clinical development of taranabant. Subsequently, numerous clinical research projects associated with CB1 antagonists were discontinued as a result of this impact, but some products continue to be developed. INV-202 is a CB1 receptor antagonist developed by Inversago Pharma. Learning from prior endeavors, Inversago Pharma's second-generation CB1 receptor antagonists are designed to reduce the permeability of the molecules through the blood-brain barrier, thereby confining the drug molecules to the peripheral system outside of the central nervous system. According to a phase 1b clinical study report updated in 2023, INV-202 showed good tolerability with no serious or severe treatment-emergent adverse events noted; the most common side effects were related to the known gastrointestinal impacts of CB1 receptor blockade. INV-202 significantly reduced average body weight by 3.5 kilograms and also notably decreased waist circumference and body mass index. In August this year, Novo Nordisk and Inversago Pharma announced that Novo Nordisk has agreed to acquire Inversago for up to $1.075 billion in cash, subject to achieving certain development and commercial milestones. Corbus Pharmaceuticals, another company dedicated to the development of drugs targeting the CB receptor system, has announced that it is working on developing a second-generation CB1 receptor antagonist, CRB-913, which is currently in the clinical declaration stage. Clinical pre-study data updated in November by the company indicate that CRB-913 has a low entry rate into the brain yet demonstrates significant weight loss effects. Ajulemic acid (Lenabasum) is another CB2 receptor agonist and IL-1β inhibitor developed by Corbus Pharmaceuticals in the United States, currently in Phase III clinical trials. Early clinical study results have indicated that Ajulemic acid can relieve pain in patients with chronic neuropathic pain without the clinically relevant psychoactive or physical side effects. Presently, this medication is being clinically investigated for a range of dermatological conditions, including discoid lupus erythematosus, dermatomyositis, systemic sclerosis, cystic fibrosis, and systemic lupus erythematosus. CardiolRx (Cannabidiol) is a CB1/CB2 inverse agonist developed by Cardiol Therapeutics. Clinical indications under investigation for this compound include cardiovascular diseases, pericarditis, myocarditis, and heart failure. CB1/CB2 Novel Drug Development StrategiesDespite the broad therapeutic potential of CB1/CB2, the development of candidate drugs is hindered by adverse reactions, rapid tolerance development, and the possibility of abuse. It has been proposed that ligands might differentiate the therapeutic effects from adverse reactions by producing biased signaling as a novel drug development strategy for the CB1/CB2 receptors. However, due to a lack of highly biased agonists, there is limited understanding of the biased signaling of the CB1 receptor. Researchers are investigating the biased signaling characteristics of classical cannabinoid agonists and isomeric ligands in search of potential therapeutic advantages of CB1 receptor biased signaling in various pathological conditions. CP55940 is a synthetic cannabinoid originally developed by Pfizer in 1974. It can mimic the effects of natural tetrahydrocannabinol, acting as an agonist for CB1/CB2 receptors. CP55940 is reported to be 45 times more potent than Δ9-THC and can be completely antagonized by Rimonabant. It is used as a research tool to study the endocannabinoid system but has never been studied clinically or sold on the market. A study published in the "Journal of Molecular Pharmacology" (DOI: 10.1124/mol.115.101980) indicates that among the several downstream signaling pathways of the CB1 receptor, agonists THC and CP55940 show a preference for signaling through β-arrestin1, whereas the endogenous cannabinoids 2-AG and AEA exhibit a preference for signaling through Gαi/o. The researchers believe that enhancing Gαi/o-based endogenous cannabinoid signaling could have therapeutic effects for Huntington's disease. In contrast, drugs that preferentially target the β-arrestin1 signaling pathway could be detrimental to therapeutic signaling downstream of the CB1 receptor, especially in patients with Huntington's disease where CB1 receptor levels are already reduced. ORG27569 is an allosteric modulator targeting the CB1 receptor. It has been reported that ORG27569 is a ligand biased towards the β-arrestin1 signaling pathway of the CB1 receptor, acting as a negative allosteric modulator in terms of G protein signaling, and as a positive allosteric modulator in the context of β-arrestin1-mediated pERK1/2 signaling. Recent research results published in the journal "Cell" (DOI: 10.1016/j.cell.2023.11.017) by Professor Zhang Yan and collaborators from Zhejiang University have filled a knowledge gap in structural biology regarding how the CB1 receptor couples to downstream β-arrestin signaling proteins.  By comparing the subtle structural differences between the inactive state bound to an antagonist, the active state with agonist-receptor-Gi protein binding, and the state with agonist-receptor-β-arrestin1 binding, the researchers seem to have found some clues about the bias of downstream CB1 receptor activation. This may provide a structural basis for designing safer analgesic and anti-anxiety medications.